What is (B) T-V7 used for?

(B) T-V7 is indicated for Atrial fibrillation for stroke prevention.

(B) T-V7 is developed by National Taiwan University Hospital.

What development phase is (B) T-V7 in?

(B) T-V7 is FDA-approved (marketed).

What are the side effects of (B) T-V7?

Common side effects include QT interval prolongation.

Last reviewed 2026-04-23 · How we verify

(B) T-V7

National Taiwan University Hospital · FDA-approved active Small molecule

T-V7 is a medication used to treat atrial fibrillation.

T-V7 is a medication used to treat atrial fibrillation. Used for Atrial fibrillation for stroke prevention.

At a glance

Generic name	(B) T-V7
Sponsor	National Taiwan University Hospital
Drug class	Antiarrhythmic
Target	Potassium channels
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

T-V7 works by blocking potassium channels in the heart, which helps to regulate heart rhythm and prevent blood clots. This is particularly useful in patients with atrial fibrillation who are at risk of stroke.

Approved indications

Atrial fibrillation for stroke prevention

Common side effects

QT interval prolongation

Key clinical trials

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(B) T-V7 CI brief — competitive landscape report
(B) T-V7 updates RSS · CI watch RSS
National Taiwan University Hospital portfolio CI